Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Sclerostin is a product of mature osteocytes embedded in mineralised bone and is a negative regulator of bone mass and osteoblast differentiation. While evidence suggests that sclerostin has an anti-anabolic role, the possibility also exists that sclerostin has catabolic activity. To test this we treated human primary pre-osteocyte cultures, cells we have found are exquisitely sensitive to sclerostin, or mouse osteocyte-like MLO-Y4 cells, with recombinant human sclerostin (rhSCL) and measured effects on pro-catabolic gene expression. Sclerostin dose-dependently up-regulated the expression of receptor activator of nuclear factor kappa B (RANKL) mRNA and down-regulated that of osteoprotegerin (OPG) mRNA, causing an increase in the RANK:OPG mRNA ratio. To examine the effects of rhSCL on resulting osteoclastic activity, MLO-Y4 cells plated onto a bone-like substrate were primed with rhSCL for 3 days and then either mouse splenocytes or human peripheral blood mononuclear cells (PBMC) were added. This resulted in cultures with elevated osteoclastic resorption (approximately 7-fold) compared to untreated co-cultures. The increased resorption was abolished by co-addition of recombinant OPG. In co-cultures of MLO-Y4 cells with PBMC, SCL also increased the number and size of the TRAP-positive multinucleated cells formed. Importantly, rhSCL had no effect on TRAP-positive cell formation from monocultures of either splenocytes or PBMC. Further, rhSCL did not induce apoptosis of MLO-Y4 cells, as determined by caspase activity assays, demonstrating that the osteoclastic response was not driven by dying osteocytes. Together, these results suggest that sclerostin may have a catabolic action through promotion of osteoclast formation and activity by osteocytes, in a RANKL-dependent manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“It achieves this by upregulating the Wnt pathway while also acting as an enhancer of RANKL synthesis, thereby downregulating this latter pathway [83,84,85].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [85]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it uniquely exhibits the ability to stimulate bone formation while simultaneously reducing bone resorption.”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [85]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Romosozumab is a newly approved monoclonal antibody targeting sclerostin.”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [85]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evidence for osteocyte regulation of bone homeostasis through RANKL expression
Nakashima, T., Hayashi, M., Fukunaga, T., Kurata, K., Oh-hora, M., Feng, J. Q., Bonewald, L. F., Kodama, T., Wutz, A., Wagner, E. F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2452 · Cited by 1,778
Self-citationWeinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753 · cited 1×
“However, glucocorticoid-induced osteocyte apoptosis is associated with reduced osteoclastogenesis [63].”
BackgroundCanonical wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
Glass, D. A., Bialek, P., Ahn, J. D., Starbuck, M., Patel, M. S., Clevers, H., Taketo, M. M., Long, F., McMahon, A. P., Lang, R. A., et al. (2005) · Developmental Cell · doi:10.1016/j.devcel.2005.02.017 · Cited by 1,558 · cited 2×
“in response to canonical [20] and potentially non-canonical [21]”
BackgroundSclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366 · cited 1×
“lipoprotein receptor (LRP)-5 and 6 [13,14].”
Mechanical Stimulation of Bone in Vivo Reduces Osteocyte Expression of Sost/Sclerostin
Robling, A. G., Niziolek, P. J., Baldridge, L. A., Condon, K. W., Allen, M. R., Alam, I., Mantila, S. M., Gluhak-Heinrich, J., Bellido, T. M., Harris, S. E., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705092200 · Cited by 1,350 · cited 1×
“loading [26] likely exert an anabolic effect, at least in part, by suppressing SCL expression.”
BackgroundMatrix-embedded cells control osteoclast formation
Xiong, J., Onal, M., Jilka, R. L., Weinstein, R. S., Manolagas, S. C., & O'Brien, C. A. (2011) · Nature Medicine · doi:10.1038/nm.2448 · Cited by 1,304
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
Winkler, D. G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg599 · Cited by 1,112 · cited 5×
“which SCL acts, are incompletely understood [7,8,9,10,11],”
BackgroundInfluentialSclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Li, X., Ominsky, M. S., Niu, Q.-T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 936 · cited 1×
“gene display an osteopetrotic phenotype [48].”
van Bezooijen, R. L., Roelen, B. A. J., Visser, A., van der Wee-Pals, L., de Wilt, E., Karperien, M., Hamersma, H., Papapoulos, S. E., ten Dijke, P., & Löwik, C. W. G. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031454 · Cited by 892
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G., Stouch, B., Fang, L., & Posvar, E. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081206 · Cited by 784 · cited 1×
“induced bone loss associated with reduced osteoclast surface [18].”
BackgroundVerborgt, O., Gibson, G. J., & Schaffler, M. B. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.60 · Cited by 731 · cited 1×
“Osteocyte cell death under certain circumstances is known to be associated with the initiation of bone resorption [59,60].”
BackgroundIdentification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
Balemans, W., Patel, N., Ebeling, M., Van Hul, E., Wuyts, W., Lacza, C., Dioszegi, M., Dikkers, F. G., Hildering, P., Willems, P. J., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.2.91 · Cited by 698 · cited 1×
“mass phenotype seen in Van Buchem’s disease [3,4,5].”
BackgroundBellido, T., Ali, A. A., Gubrij, I., Plotkin, L. I., Fu, Q., O’Brien, C. A., Manolagas, S. C., & Jilka, R. L. (2005) · Endocrinology · doi:10.1210/en.2005-0239 · Cited by 641 · cited 1×
“Parathyroid hormone (PTH) treatment [24,25] and mechanical”
Osteocyte Wnt/β-Catenin Signaling Is Required for Normal Bone Homeostasis
Kramer, I., Halleux, C., Keller, H., Pegurri, M., Gooi, J. H., Weber, P. B., Feng, J. Q., Bonewald, L. F., & Kneissel, M. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01428-09 · Cited by 567 · cited 1×
“colleagues [52] demonstrated that conditional deletion of the gene encoding b-catenin in osteocytes, under control of the osteocytespecific Dmp1 promoter, resulted in a severe low bone mass”
BackgroundSelf-citationEstablishment of an osteocyte-like cell line, MLO-Y4
Kato, Y., Windle, J. J., Koop, B. A., Mundy, G. R., & Bonewald, L. F. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.12.2014 · Cited by 500 · cited 2×
“MLOY4 cells were passaged solely on type I collagen-coated plates, as described previously [37].”
BackgroundMethodSelf-citationGenomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
Loots, G. G., Kneissel, M., Keller, H., Baptist, M., Chang, J., Collette, N. M., Ovcharenko, D., Plajzer-Frick, I., & Rubin, E. M. (2005) · Genome Research · doi:10.1101/gr.3437105 · Cited by 442 · cited 1×
“Of note, histomorphometric analysis of Sost-overexpressing (transgenic) mice revealed an osteopenic phenotype but with no apparent effect on TRAP osteoclast number [53,54].”
BackgroundThe Death of Osteocytes via Apoptosis Accompanies Estrogen Withdrawal in Human Bone
Tomkinson, A. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.9.3128 · Cited by 416 · cited 1×
“Osteocyte cell death under certain circumstances is known to be associated with the initiation of bone resorption [59,60].”
BackgroundMedina, V., Edmonds, B., Young, G. P., James, R., Appleton, S., & Zalewski, P. D. (1997) · PubMed · Cited by 377
Osteocyte Apoptosis Controls Activation of Intracortical Resorption in Response to Bone Fatigue
Cardoso, L., Herman, B. C., Verborgt, O., Laudier, D., Majeska, R. J., & Schaffler, M. B. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081210 · Cited by 340 · cited 1×
“Prevention of bone fatigue-induced osteocyte apoptosis has been show to block associated osteoclastic resorption [62].”
BackgroundMLO-Y4 Osteocyte-Like Cells Support Osteoclast Formation and Activation
Zhao, S., Kato, Y., Zhang, Y., Harris, S., Ahuja, S. S., & Bonewald, L. F. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.11.2068 · Cited by 322 · cited 2×
“Furthermore the osteocyte cell line, MLO-Y4, can express RANKL and support osteoclastogenesis [31,32].”
BackgroundMethodSelf-citationGaudio, A., Pennisi, P., Bratengeier, C., Torrisi, V., Lindner, B., Mangiafico, R. A., Pulvirenti, I., Hawa, G., Tringali, G., & Fiore, C. E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0067 · Cited by 315 · cited 1×
“6 ng/ml [49,50,51].”
Bone Overgrowth-associated Mutations in the LRP4 Gene Impair Sclerostin Facilitator Function
Leupin, O., Piters, E., Halleux, C., Hu, S., Kramer, I., Morvan, F., Bouwmeester, T., Schirle, M., Bueno-Lozano, M., Ramos Fuentes, F. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.190330 · Cited by 301
Staehling‐Hampton, K., Proll, S., Paeper, B. W., Zhao, L., Charmley, P., Brown, A., Gardner, J. C., Galas, D., Schatzman, R. C., Beighton, P., et al. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10401 · Cited by 294 · cited 1×
“mass phenotype seen in Van Buchem’s disease [3,4,5].”
Backgroundvan Bezooijen, R. L., Svensson, J. P., Eefting, D., Visser, A., van der Horst, G., Karperien, M., Quax, P. H., Vrieling, H., Papapoulos, S. E., ten Dijke, P., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061002 · Cited by 283
Gronthos, S., Zannettino, A. C. W., Graves, S. E., Ohta, S., Hay, S. J., & Simmons, P. J. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.1.47 · Cited by 282 · cited 9×
“Gene expression experiments To determine the ability of NHBC to form a mineralised matrix, a modification of a method reported previously [43] was used.”
MethodInfluentialKusu, N., Laurikkala, J., Imanishi, M., Usui, H., Konishi, M., Miyake, A., Thesleff, I., & Itoh, N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301716200 · Cited by 274 · cited 1×
“which SCL acts, are incompletely understood [7,8,9,10,11],”
Atkins, G. J., Anderson, P. H., Findlay, D. M., Welldon, K. J., Vincent, C., Zannettino, A. C. W., O'Loughlin, P. D., & Morris, H. A. (2007) · Bone · doi:10.1016/j.bone.2007.02.024 · Cited by 252
Self-citationEffects of Parathyroid Hormone Treatment on Circulating Sclerostin Levels in Postmenopausal Women
Drake, M. T., Srinivasan, B., Mödder, U. I., Peterson, J. M., McCready, L. K., Riggs, B. L., Dwyer, D., Stolina, M., Kostenuik, P., & Khosla, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0720 · Cited by 251 · cited 1×
“6 ng/ml [49,50,51].”
Parathyroid hormone (PTH)–induced bone gain is blunted in SOST overexpressing and deficient mice
Kramer, I., Loots, G. G., Studer, A., Keller, H., & Kneissel, M. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090730 · Cited by 247 · cited 1×
“Of note, histomorphometric analysis of Sost-overexpressing (transgenic) mice revealed an osteopenic phenotype but with no apparent effect on TRAP osteoclast number [53,54].”
BackgroundRANKL Expression Is Related to the Differentiation State of Human Osteoblasts
Atkins, G. J., Kostakis, P., Pan, B., Farrugia, A., Gronthos, S., Evdokiou, A., Harrison, K., Findlay, D. M., & Zannettino, A. C. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.6.1088 · Cited by 245 · cited 1×
“Adult human primary osteoblasts (normal human bone-derived cells; NHBC [38]) were isolated from femoral neck trabecular bone and passaged, as we have described previously [39].”
MethodSelf-citationAtkins, G. J., Rowe, P. S., Lim, H. P., Welldon, K. J., Ormsby, R., Wijenayaka, A. R., Zelenchuk, L., Evdokiou, A., & Findlay, D. M. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.345 · Cited by 240 · cited 6×
“Consistent with our previous studies [33,35,36], this analysis showed that osteoblasts acquired the expected gene profile consistent with differentiation into mature cells with an osteocyte-like phenotype, including time-dependent increases in mRNA levels of the markers DMP1 and SOST (Fig.”
BackgroundMethodResultSelf-citationSclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation
Sutherland, M. K., Geoghegan, J. C., Yu, C., Turcott, E., Skonier, J. E., Winkler, D. G., & Latham, J. A. (2004) · Bone · doi:10.1016/j.bone.2004.05.023 · Cited by 238
Regulation of circulating sclerostin levels by sex steroids in women and in men
Mödder, U. I., Clowes, J. A., Hoey, K., Peterson, J. M., McCready, L., Oursler, M. J., Riggs, B. L., & Khosla, S. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.128 · Cited by 229 · cited 1×
“6 ng/ml [49,50,51].”
ten Dijke, P., Krause, C., de Gorter, D. J. J., Löwik, C. W. G. M., & van Bezooijen, R. L. (2008) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.g.01183 · Cited by 224
Wnt Signaling: A Key Regulator of Bone Mass
Baron, R., Rawadi, G., & Roman‐Roman, S. (2006) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)76004-5 · Cited by 219 · cited 1×
“which cause the high bone mass disease in humans, sclerosteosis [1].”
BackgroundKogianni, G., Mann, V., & Noble, B. S. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080207 · Cited by 215 · cited 2×
“In addition, Kogianni and colleagues [61] reported that osteoclast formation in response to osteocyte apoptotic bodies could not be inhibited with exogenous OPG, whereas in our study the proosteoclastic effects of SCL were strictly RANKL-dependent.”
BackgroundChoi, H. Y., Dieckmann, M., Herz, J., & Niemeier, A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007930 · Cited by 208 · cited 1×
“has also been implicated as a major receptor for SCL [15,16].”
BackgroundAtkins, G. J., Welldon, K. J., Halbout, P., & Findlay, D. M. (2009) · Osteoporosis International · doi:10.1007/s00198-008-0728-6 · Cited by 200 · cited 2×
“Consistent with our previous studies [33,35,36], this analysis showed that osteoblasts acquired the expected gene profile consistent with differentiation into mature cells with an osteocyte-like phenotype, including time-dependent increases in mRNA levels of the markers DMP1 and SOST (Fig.”
BackgroundResultSelf-citationThe proliferation and phenotypic expression of human osteoblasts on tantalum metal
Findlay, D. M., Welldon, K., Atkins, G. J., Howie, D. W., Zannettino, A. C. W., & Bobyn, D. (2004) · Biomaterials · doi:10.1016/j.biomaterials.2003.09.005 · Cited by 189 · cited 2×
“Media containing all supplements were replaced every 4 days and cells were cultured for up to 6 weeks before measurement of cell layer-associated Ca levels, as described previously [43].”
MethodSelf-citationVincent, C., Findlay, D. M., Welldon, K. J., Wijenayaka, A. R., Zheng, T. S., Haynes, D. R., Fazzalari, N. L., Evdokiou, A., & Atkins, G. J. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090305 · Cited by 180 · cited 3×
“It also remains to be seen which of the proposed receptors for SCL, including the LRPs 4, 5 and 6, are important for the responses observed in our study and whether the effect is dependent on canonical or non-canonical Wnt signalling, or indeed on BMP [8,12] and/or MAPK [17] signalling.”
BackgroundSelf-citationDistinct Modes of Inhibition by Sclerostin on Bone Morphogenetic Protein and Wnt Signaling Pathways
Krause, C., Korchynskyi, O., de Rooij, K., Weidauer, S. E., de Gorter, D. J. J., van Bezooijen, R. L., Hatsell, S., Economides, A. N., Mueller, T. D., Löwik, C. W. G. M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.153890 · Cited by 178 · cited 3×
“It also remains to be seen which of the proposed receptors for SCL, including the LRPs 4, 5 and 6, are important for the responses observed in our study and whether the effect is dependent on canonical or non-canonical Wnt signalling, or indeed on BMP [8,12] and/or MAPK [17] signalling.”
BackgroundWinkler, D. G., Sutherland, M. S. K., Ojala, E., Turcott, E., Geoghegan, J. C., Shpektor, D., Skonier, J. E., Yu, C., & Latham, J. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m400524200 · Cited by 164 · cited 1×
“which SCL acts, are incompletely understood [7,8,9,10,11],”
Kogawa, M., Findlay, D. M., Anderson, P., Ormsby, R. T., Vincent, C., Morris, H. A., & Atkins, G. J. (2010) · Endocrinology · doi:10.1210/en.2010-0334 · Cited by 153 · cited 5×
“Alternatively, cells were seeded at an identical density onto slices of whale dentine or into wells of Osteologic slides for the purpose of quantification of resorptive activity [40,41].”
BackgroundMethodSelf-citationMechanical stimulation in vivo reduces osteocyte expression of sclerostin.
Robling, A. G., Bellido, T., & Turner, C. H. (2006) · PubMed · Cited by 141
Sclerostin in Mineralized Matrices and van Buchem Disease
van Bezooijen, R. L., Bronckers, A. L., Gortzak, R. A., Hogendoorn, P. C. W., van der Wee-Pals, L., Balemans, W., Oostenbroek, H. J., Van Hul, W., Hamersma, H., Dikkers, F. G., et al. (2009) · Journal of Dental Research · doi:10.1177/0022034509338340 · Cited by 138
Kurata, K., Heino, T. J., Higaki, H., & Väänänen, H. K. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060106 · Cited by 133
Atkins, G. J., Welldon, K. J., Wijenayaka, A. R., Bonewald, L. F., & Findlay, D. M. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00216.2009 · Cited by 132 · cited 2×
“Consistent with our previous studies [33,35,36], this analysis showed that osteoblasts acquired the expected gene profile consistent with differentiation into mature cells with an osteocyte-like phenotype, including time-dependent increases in mRNA levels of the markers DMP1 and SOST (Fig.”
BackgroundResultSelf-citationAtkins, G. J., Kostakis, P., Vincent, C., Farrugia, A. N., Houchins, J. P., Findlay, D. M., Evdokiou, A., & Zannettino, A. C. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060604 · Cited by 131
Self-citationAtkins, G. J., Welldon, K. J., Holding, C. A., Haynes, D. R., Howie, D. W., & Findlay, D. M. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.03.035 · Cited by 121 · cited 2×
“We have established a model of human osteocytes, with many of the molecular and phenotypic characteristics of osteocytes, by allowing normal human bone derived osteoblastic cells (NHBC) to differentiate in long-term (4 to 5 weeks) culture [33,34,35].”
BackgroundMethodSelf-citationSilvestrini, G., Ballanti, P., Leopizzi, M., Sebastiani, M., Berni, S., Vito, M. D., & BONUCCI, E. (2007) · Journal of Molecular Histology · doi:10.1007/s10735-007-9096-3 · Cited by 118 · cited 1×
“Parathyroid hormone (PTH) treatment [24,25] and mechanical”
Ikeda, T., Utsuyama, M., & Hirokawa, K. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.8.1416 · Cited by 107 · cited 1×
“Osteocytes can express RANKL in vivo [28,29,30].”
Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts
Sutherland, M. K., Geoghegan, J. C., Yu, C., Winkler, D. G., & Latham, J. A. (2004) · Bone · doi:10.1016/j.bone.2004.04.019 · Cited by 93 · cited 1×
“which SCL acts, are incompletely understood [7,8,9,10,11],”
Jäger, A., Götz, W., Lossdörfer, S., & Rath-Deschner, B. (2009) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.2009.01227.x · Cited by 78 · cited 1×
“Since the expression of SCL in vivo is by mature, mineral embedded osteocytes [8,22,57,58], we propose that neighboring osteocytes, those in closer proximity to endosteal surfaces than osteocytes expressing high levels of SCL [22], may respond to a local, catabolic stimulus-driven increase in SCL.”
BackgroundShiotani, A., Shibasaki, Y., & Sasaki, T. (2001) · QJM · doi:10.1093/jmicro/50.4.365 · Cited by 77 · cited 1×
“Osteocytes can express RANKL in vivo [28,29,30].”
DeLuca, H. F. (1979) · Monographs on endocrinology · doi:10.1007/978-3-642-81306-1_4 · Cited by 74
Wnt modulators in the biotech pipeline
Rey, J., & Ellies, D. L. (2010) · Developmental Dynamics · doi:10.1002/dvdy.22181 · Cited by 71 · cited 1×
“Accumulating evidence suggests that SCL is a key determinant of bone mass in humans and blockage of SCL activity is currently being explored as a novel treatment option for osteoporosis [6,46,47].”
BackgroundHuman osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis
Atkins, G. J., Bouralexis, S., Evdokiou, A., Hay, S. J., Labrinidis, A., Zannettino, A. C. W., Haynes, D. R., & Findlay, D. M. (2002) · Bone · doi:10.1016/s8756-3282(02)00858-x · Cited by 67 · cited 2×
“The effect of rhSCL in this regard was tested against the cytotoxic drug, etoposide at a concentration (50 mM) we shown previously to induce apoptosis in osteoblastic cell lines [45].”
BackgroundMethodSelf-citationTian, X., Setterberg, R. B., Li, X., Pászty, C., Ke, H. Z., & Jee, W. S. S. (2010) · Bone · doi:10.1016/j.bone.2010.05.032 · Cited by 61 · cited 1×
“surface) in these animals [19], consistent with an effect of sclerostin”
ResultWnt modulators in the biotech pipeline
Rey, J., & Ellies, D. L. (2010) · Developmental Dynamics · doi:10.1002/dvdy.22249 · Cited by 37
Kaneuji, T., Ariyoshi, W., Okinaga, T., Toshinaga, A., Takahashi, T., & Nishihara, T. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.03.128 · Cited by 36
A new paradigm in the treatment of osteoporosis: Wnt pathway proteins and their antagonists.
Chan, A. B., van Bezooijen, R. L., & Löwik, C. W. G. M. (2007) · PubMed · Cited by 25
TWEAK and TNF Regulation of Sclerostin: A Novel Pathway for the Regulation of Bone Remodelling
Findlay, D. M., & Atkins, G. J. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6612-4_34 · Cited by 17 · cited 1×
“In contrast, catabolic stimuli appear to increase SCL expression in bone, for example mechanical unloading [23] or exposure of osteoblast-lineage cells to proinflammatory cytokines such as tumour necrosis factor-alpha (TNFa) and TNF-related weak inducer of apoptosis (TWEAK) [17,27].”
BackgroundSelf-citationMueller, R. J., & Richards, R. G. (2004) · Journal of Materials Science Materials in Medicine · doi:10.1023/b:jmsm.0000021103.39114.cd · Cited by 17 · cited 1×
“Osteocytes can express RANKL in vivo [28,29,30].”
Kogawa, M., Findlay, D. M., Anderson, P., Ormsby, R. T., Vincent, C., Morris, H. A., & Atkins, G. J. (2010) · Endocrine Reviews · doi:10.1210/edrv.31.5.9978 · Cited by 11
Self-citation
Cited by
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805
RANKL biology: bone metabolism, the immune system, and beyond
Ono, T., Hayashi, M., Sasaki, F., & Nakashima, T. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-019-0111-3 · Cited by 578
“In addition, sclerostin was shown to induce RANKL expression [45, 46], and romosozumab decrease bone resorption via its inhibition.”
BackgroundHan, Y., You, X., Xing, W., Zhang, Z., & Zou, W. (2018) · Bone Research · doi:10.1038/s41413-018-0019-6 · Cited by 576
An overview of the regulation of bone remodelling at the cellular level
Kular, J., Tickner, J., Chim, S. M., & Xu, J. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.03.021 · Cited by 534
“Besides acting on osteoblasts, a recent study suggests that sclerostin can also promote osteoclast formation and activity in a RANKL dependent manner [94].”
BackgroundRole and mechanism of action of sclerostin in bone
Delgado-Calle, J., Sato, A. Y., & Bellido, T. (2017) · Bone · doi:10.1016/j.bone.2016.10.007 · Cited by 443
“These results are in line with earlier findings indicating that recombinant sclerostin upregulates Rankl and increases osteoclast formation in vitro (93).”
Metadata
- Authors
- Wijenayaka, A. R., Kogawa, M., Lim, H. P., Bonewald, L. F., Findlay, D. M., & Atkins, G. J.
- Affiliations
- Hanson Institute (AU)
- University of Missouri–Kansas City (US)
- Corresponding author
- Atkins, Gerald J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-10-04
- Volume
- 6
- Issue
- 10
- Pages
- e25900
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3186800
- OpenAlex
- W2028910660
- Cited by
- 503
- References
- 66
- Citations by year
- 2026: 22 · 2025: 21 · 2024: 26 · 2023: 33 · 2022: 33 · 2021: 33 · 2020: 57 · 2019: 49 · 2018: 37 · 2017: 37 · 2016: 37 · 2015: 29 · 2014: 33 · 2013: 32 · 2012: 22
- FWCI
- 11.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Royal Adelaide Hospital
- Medical Research Council
- National Health and Medical Research Council (565372)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Bone and Dental Protein Studies
- Keywords
- sclerostin, osteocytes, osteoclasts, RANKL, osteoprotegerin, bone resorption, osteoclastogenesis, bone catabolism, MLO-Y4 cells, TRAP-positive multinucleated cells, osteocyte apoptosis
- MeSH terms
- Tartrate-Resistant Acid Phosphatase, Acid Phosphatase, Adult, Animals, Calcification, Physiologic, Cell Differentiation, Cell Survival, Cells, Cultured, Gene Expression Regulation, Genetic Markers, Humans, Isoenzymes, Osteoblasts, Osteoclasts, Osteocytes, Osteogenesis, Recombinant Proteins, Signal Transduction, Apoptosis, Bone Morphogenetic Proteins, Adaptor Proteins, Signal Transducing, Mice, RANK Ligand
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.